Literature DB >> 8697643

The relationship between exposed galactose and N-acetylglucosamine residues on IgG in rheumatoid arthritis (RA), juvenile chronic arthritis (JCA) and Sjögren's syndrome (SS).

A Bond1, A Alavi, J S Axford, P Youinou, F C Hay.   

Abstract

The relationship between exposed galactose and N-acetylglucosamine on IgG in RA, JCA and SS was investigated. This was achieved using IgG isolated from serum where the levels of galactose and N-acetylglucosamine (GlcNAc) were detected using biotinylated lectins. Galactose and GlcNAc on IgG from patients with RA and JCA are inversely related, but in contrast, in SS, galactose expression on IgG decreased while GlcNAc expression remained similar to normal levels. Alterations in IgG glycosylation are closely associated with the development of adult and juvenile chronic arthritis and SS, but the changes involved are different in RA compared with SS, suggesting that the precise pattern of exposed sugars is associated with different rheumatological diseases.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8697643      PMCID: PMC2200464          DOI: 10.1046/j.1365-2249.1996.d01-741.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  19 in total

Review 1.  Intravenous immunoglobulin-mediated immunosuppression and the development of an IVIG substitute.

Authors:  Miglena G Prabagar; Hyeong-jwa Choi; Jin-Yeon Park; Sohee Loh; Young-Sun Kang
Journal:  Clin Exp Med       Date:  2013-09-01       Impact factor: 3.984

Review 2.  Glycobiology and medicine: an introduction.

Authors:  J Axford
Journal:  J R Soc Med       Date:  1997-05       Impact factor: 5.344

Review 3.  Molecular Analysis of Inflammatory Bowel Disease: Clinically Useful Tools for Diagnosis, Response Prediction, and Monitoring of Targeted Therapy.

Authors:  Weiwei Jiang; Xuhang Li
Journal:  Mol Diagn Ther       Date:  2015-06       Impact factor: 4.074

4.  The changes in monosaccharide composition of immunoglobulin G in the course of rheumatoid arthritis.

Authors:  Ewa Gindzienska-Sieskiewicz; Piotr Adrian Klimiuk; Dariusz Gabriel Kisiel; Andrzej Gindzienski; Stanislaw Sierakowski
Journal:  Clin Rheumatol       Date:  2006-08-04       Impact factor: 2.980

Review 5.  Molecular basis for downregulation of C5a-mediated inflammation by IgG1 immune complexes in allergy and asthma.

Authors:  Manoj Kumar Pandey
Journal:  Curr Allergy Asthma Rep       Date:  2013-12       Impact factor: 4.806

6.  Anti-agalactosyl IgG antibody in ankylosing spondylitis and psoriatic arthritis.

Authors:  Chen-Liang Chou; Min-Jung Wu; Chia-Li Yu; Ming-Chi Lu; Song-Chou Hsieh; Tsai-Hung Wu; Chung-Tei Chou; Chang-Youh Tsai
Journal:  Clin Rheumatol       Date:  2010-03-14       Impact factor: 2.980

7.  Altered expression and glycosylation of plasma proteins in rheumatoid arthritis.

Authors:  Sunil K Raghav; Bhawna Gupta; Charu Agrawal; Ashish Saroha; Rakha H Das; Ved P Chaturvedi; Hasi R Das
Journal:  Glycoconj J       Date:  2006-05       Impact factor: 2.916

8.  Multiple juvenile idiopathic arthritis subtypes demonstrate proinflammatory IgG glycosylation.

Authors:  Altan Ercan; Michael G Barnes; Melissa Hazen; Heather Tory; Lauren Henderson; Fatma Dedeoglu; Robert C Fuhlbrigge; Alexei Grom; Ingrid A Holm; Mark Kellogg; Susan Kim; Barbara Adamczyk; Pauline M Rudd; Mary Beth Son; Robert P Sundel; Dirk Foell; David N Glass; Susan D Thompson; Peter A Nigrovic
Journal:  Arthritis Rheum       Date:  2012-09

9.  Abnormal glycosylation of serum IgG in patients with IgA nephropathy.

Authors:  Hideki Homma; Keiichi Tozawa; Takahiro Yasui; Yasunori Itoh; Yutaro Hayashi; Kenjiro Kohri
Journal:  Clin Exp Nephrol       Date:  2006-09       Impact factor: 2.801

10.  High-throughput characterization of the functional impact of IgG Fc glycan aberrancy in juvenile idiopathic arthritis.

Authors:  Hao D Cheng; Henning Stöckmann; Barbara Adamczyk; Ciara A McManus; Altan Ercan; Ingrid A Holm; Pauline M Rudd; Margaret E Ackerman; Peter A Nigrovic
Journal:  Glycobiology       Date:  2017-12-01       Impact factor: 4.313

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.